Overview

Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease

Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to gather scientific information about the effectiveness and safety of the study drug, Ecopipam (PSYRX 101), for the treatment of self-injurious behaviors when compared with the effectiveness and safety of placebo (inactive substance) in subjects with Lesch-Nyhan Disease.
Phase:
Phase 3
Details
Lead Sponsor:
Psyadon Pharma
Treatments:
Ecopipam